Xerostomia Epidemiology Forecast

DelveInsight's 'Xerostomia - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Xerostomia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Xerostomia Understanding

The DelveInsight Xerostomia epidemiology report gives a thorough understanding of the Xerostomia by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Xerostomia in the US, Europe, and Japan. The report covers the detailed information of the Xerostomia epidemiology scenario in seven major countries (US, EU5, and Japan).


Xerostomia Epidemiology Perspective by DelveInsight

The Xerostomia epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Xerostomia epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Xerostomia epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.


Xerostomia Detailed Epidemiology Segmentation

The Xerostomia epidemiology covered in the report provides historical as well as forecasted Xerostomia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Xerostomia report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.


Scope of the Report

  • The Xerostomia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Xerostomia Epidemiology Report and Model provide an overview of the risk factors and global trends of Xerostomia in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Xerostomia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Xerostomia
  • The report provides the segmentation of the Xerostomia epidemiology


Report Highlights

  • 11-Year Forecast of Xerostomia epidemiology
  • 7MM Coverage
  • Total Cases of Xerostomia
  • Total Cases of Xerostomia according to segmentation
  • Diagnosed cases of Xerostomia


KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Xerostomia?
  • What are the key findings pertaining to the Xerostomia epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Xerostomia across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Xerostomia?
  • What are the currently available treatments of Xerostomia?


Reasons to buy

  • The Xerostomia Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Xerostomia market
  • Quantify patient populations in the global Xerostomia market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Xerostomia therapeutics in each of the markets covered
  • Understand the magnitude of Xerostomia population by its epidemiology
  • The Xerostomia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights 

2. Executive Summary of Xerostomia

3. Xerostomia: Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Xerostomia Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Xerostomia Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Xerostomia Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Xerostomia Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Xerostomia Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Xerostomia Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Xerostomia Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Xerostomia Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Xerostomia Treatment and Management

6.2. Xerostomia Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

Table 1  Xerostomia Epidemiology in 7MM (2017-2030)

Table 2 Xerostomia Diagnosed and Treatable Cases in 7MM (2017-2030)

Table 3 Xerostomia Epidemiology in the United States (2017-2030)

Table 4 Xerostomia Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 Xerostomia Epidemiology in Germany (2017-2030)

Table 6 Xerostomia Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 Xerostomia Epidemiology in France (2017-2030)

Table 8 Xerostomia Diagnosed and Treatable Cases in France (2017-2030)

Table 9 Xerostomia Epidemiology in Italy (2017-2030)

Table 10 Xerostomia Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 Xerostomia Epidemiology in Spain (2017-2030)

Table 12 Xerostomia Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 Xerostomia Epidemiology in the United Kingdom (2017-2030)

Table 14 Xerostomia Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Table 15 Xerostomia Epidemiology in Japan (2017-2030)

Table 16 Xerostomia Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 1 Xerostomia Epidemiology in 7MM (2017-2030)

Figure 2 Xerostomia Diagnosed and Treatable Cases in 7MM (2017-2030)

Figure 3 Xerostomia Epidemiology in the United States (2017-2030)

Figure 4 Xerostomia Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 Xerostomia Epidemiology in Germany (2017-2030)

Figure 6 Xerostomia Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 Xerostomia Epidemiology in France (2017-2030)

Figure 8 Xerostomia Diagnosed and Treatable Cases in France (2017-2030)

Figure 9 Xerostomia Epidemiology in Italy (2017-2030)

Figure 10 Xerostomia Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 Xerostomia Epidemiology in Spain (2017-2030)

Figure 12 Xerostomia Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 Xerostomia Epidemiology in the United Kingdom (2017-2030)

Figure 14 Xerostomia Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Figure 15 Xerostomia Epidemiology in Japan (2017-2030)

Figure 16 Xerostomia Diagnosed and Treatable Cases in Japan (2017-2030)

*The table of contents is not exhaustive; will be provided in the final report



  • Tags:
  • Xerostomia Epidemiology
  • Xerostomia
  • Xerostomia Pipeline
  • Xerostomia Companies
  • Xerostomia prevalent population
  • Xerostomia incident population
  • Xerostomia patients diagnosed
  • Xerostomia treatment algorithm

Forward to Friend

Need A Quote